Rising Prevalence of HIV Infection
According to the World Health Organization (WHO), it is estimated that in 2015, nearly 36.7 million individuals had HIV. It has been identified that most of this prevalence is in low and middle-income countries. According to UNAIDS in 2016, around 1.8 million people with new HIV infection were reported worldwide. In 2017, 20.9 million people were accessing antiretroviral therapy, globally. The huge patient pool indicates high demand for anti-viral drugs, which will likely drive the market growth during the forecast period.
Other factors that drive the market include increasing initiatives by public and private companies, advancements in molecular biology promoting drug development, and a strong pipeline for antiviral drugs.
Therapeutics Going Off-patent
Therapeutics losing patent exclusivity affects the market largely. Along with the innovator company, there are many regional/local players in the market. Due to this, the prices of the Therapeutics come down rapidly and the overall market gets affected. In the year 2016 itself, quite a few HIV Therapeutics had gone off-patent. Epzicom, Trizivir, Norvir, and Kaletra lost patent exclusivity in 2016. Abbott’s Kaletra has more than 8% share in the HIV anti-virals market. This will greatly affect the market for anti-viral drugs. The high cost of anti-viral drug treatment also hinders the growth of the market.
North America to Dominate the Market
North America dominates the global anti-viral Therapeutics market owing to the presence of well-established market players, and growing prevalence of HIV and Hepatitis C infections. Asia-Pacific is expected to grow tremendously during the forecast period owing to factors, such as high prevalence of HIV infection, growing awareness regarding HIV infection, and increasing collaboration between public and private sectors to provide affordable treatment to the low and middle-income countries.
Key Developments in the Market
- February 2018: Gilead Sciences Inc received approval from US Food and Drug Administration (FDA), for Biktarvy, a daily single tablet regimen (STR) for the treatment of HIV-1 infection.
- August 2017: AbbVie received approval from US Food and Drug Administration, for MAVYRET (glecaprevir/pibrentasvir), treatment for adults with chronic hepatitis C virus (HCV) infection.
PFIZER INC., SANOFI, AND JOHNSON & JOHNSON, amongst others.
Reasons to Purchase this Report
- Current and future global anti-viral Therapeutics market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares and strategies employed by the major market players
- 3 months analyst support along with the Market Estimate sheet (in Excel)
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Initiatives by Public and Private Companies
6.1.2 Advancements in Molecular Biology Promoting Drug Development
6.1.3 Rising Prevalence of HIV Infection
6.1.4 Strong Pipeline for Antiviral Drugs
6.2 Market Restraints
6.2.1 Drugs going off-Patent
6.2.2 High Cost of Antiviral Drug Treatment
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation -By Drug Type
7.1.1 Herpes Antiviral Drugs
7.1.2 Hepatitis Antiviral Drugs
7.1.3 HIV Antiviral Drugs
18.104.22.168 Emtricitabine and Tenofovir disoproxil fumarate
22.214.171.124 Lopinavir & Ritonavir
126.96.36.199 Abacavir & lamivudine
188.8.131.52 Lamivudine & Zidovudine
7.1.4 Influenza Antiviral Drugs
184.108.40.206 Oseltamivir phosphate
7.1.5 Others Antiviral Drugs
7.2 Segmentation -By Distribution Channel
7.2.1 Hospital Pharmacy
7.2.2 Independent Pharmacy and Drug Store
7.2.3 Online Pharmacy
7.3 Segmentation - by Geography
7.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest Of Europe
126.96.36.199 Australia & New Zealand
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
7.3.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of the Middle East & Africa
7.3.5 South America
22.214.171.124 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 AbbVie, Inc.
9.2 Bristol-Meyrs Squibb Company
9.3 Cipla, Inc.
9.4 F. Hoffmann-La Roche Ltd.
9.5 Gilead Sciences Inc
9.6 GlaxoSmithKline plc
9.7 Johnson & Johnson
9.8 Merck & Co., Inc.
9.9 Pfizer Inc.
10. Future of the Market